{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:43:26Z","timestamp":1789389806393,"version":"build-2803163510"},"reference-count":91,"publisher":"FapUNIFESP (SciELO)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Soc. Bras. Med. Trop."],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1590\/0037-8682-0120-2016","type":"journal-article","created":{"date-parts":[[2016,8,31]],"date-time":"2016-08-31T18:02:27Z","timestamp":1472666547000},"page":"398-407","source":"Crossref","is-referenced-by-count":51,"title":["Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis"],"prefix":"10.1590","volume":"49","author":[{"given":"Mariana Costa","family":"Duarte","sequence":"first","affiliation":[{"name":"Universidade Federal de Minas Gerais, Brazil; Universidade Federal de Minas Gerais, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela Pagliara","family":"Lage","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edvian Tamietti","family":"Martins","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel","family":"Ch\u00e1vez-Fumagalli","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno Mendes","family":"Roatt","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Menezes-Souza","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais, Brazil; Universidade Federal de Minas Gerais, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Ricardo","family":"Goulart","sequence":"additional","affiliation":[{"name":"Universidade Federal de Uberl\u00e2ndia, Brazil; University of California-Davis, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Soto","sequence":"additional","affiliation":[{"name":"Universidad Aut\u00f3noma de Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Alberto Pereira","family":"Tavares","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Antonio Ferraz","family":"Coelho","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais, Brazil; Universidade Federal de Minas Gerais, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1128\/CMR.6.3.230","article-title":"Leishmaniases of the New World: current concepts and implications for future research","volume":"6","author":"Grimaldi Jr G","year":"1993","journal-title":"Clin Microbiol Rev"},{"key":"ref2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar J","year":"2012","journal-title":"PLoS One"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2174\/092986709787458489","article-title":"Leishmaniasis: current treatment and prospects for new drugs and vaccines","volume":"16","author":"Kedzierski L","year":"2009","journal-title":"Curr Med Chem"},{"key":"ref4","first-page":"22","article-title":"Control of the leishmaniases. Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniases","volume":"949","year":"2010","journal-title":"World Health Organ Tech Rep Ser"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3389\/fimmu.2014.00272","article-title":"Immunotherapy and immunochemotherapy in visceral leishmaniasis: promising treatments for this neglected disease","volume":"5","author":"Roatt BM","year":"2014","journal-title":"Front Immunol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.actatropica.2011.05.012","article-title":"Importance of worldwide asymptomatic carriers of Leishmania infantum (L. chagasi) in human","volume":"119","author":"Michel G","year":"2011","journal-title":"Acta Trop"},{"key":"ref7","first-page":"378","article-title":"Liposomal amphotericin B versus pentavalent antimony salts for visceral Leishmania in children","volume":"55","author":"Apa H","year":"2013","journal-title":"Turk J Pediatr"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/00034983.1998.11813313","article-title":"Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases","volume":"92","author":"Thakur CP","year":"1998","journal-title":"Ann Trop Med Parasitol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1086\/318121","article-title":"Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic","volume":"31","author":"Sundar S","year":"2000","journal-title":"Clin Infect Dis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.pt.2003.09.008","article-title":"Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs","volume":"19","author":"Croft SL","year":"2003","journal-title":"Trends Parasitol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/jac\/dkn549","article-title":"Retrospective evaluation of amphotericin B deoxycholate toxicity in a single centre series of haematopoietic stem cell transplantation recipients","volume":"63","author":"Annaloro C","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejps.2015.01.015","article-title":"Nanoemulsions loaded with amphotericin B: a new approach for the treatment of leishmaniasis","volume":"70","author":"Caldeira LR","year":"2015","journal-title":"Eur J Pharm Sci"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1590\/0037-8682-0138-2015","article-title":"New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment","volume":"48","author":"Ch\u00e1vez-Fumagalli MA","year":"2015","journal-title":"Rev Soc Bras Med Trop"},{"key":"ref14","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/427655ac-c278-41f5-95ca-6279c562752f","article-title":"Antigenicity and protective efficacy of a Leishmania amastigote-specific protein, member of the super-oxygenase family, against visceral leishmaniasis","volume":"7","author":"Martins VT","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00436-011-2680-1","article-title":"Diagnosis of visceral leishmaniasis: developments over the last decade","volume":"110","author":"Srividya G","year":"2012","journal-title":"Parasitol Res"},{"key":"ref16","first-page":"281","article-title":"In search of an ideal test for diagnosis and prognosis of kala-azar","volume":"28","author":"Singh DP","year":"2010","journal-title":"J Health Popul Nutr"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1128\/CVI.00465-15","article-title":"Proteins selected in Leishmania (Viannia) braziliensis by an immunoproteomic approach with potential serodiagnosis applications for tegumentary leishmaniasis","volume":"22","author":"Duarte MC","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1590\/S0074-02762012000700019","article-title":"Use of the Kala-Azar Detect(r) and IT-LEISH(r) rapid tests for the diagnosis of visceral leishmaniasis in Brazil","volume":"107","author":"Peruhype-Magalh\u00e3es V","year":"2012","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"ref19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002322","article-title":"rKLO8, a novel Leishmania donovani - derived recombinant immunodominant protein for sensitive detection of visceral leishmaniasis in Sudan","volume":"7","author":"Abass E","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1586\/14760584.2016.1105135","article-title":"Leishmania vaccine development: exploiting the host-vector-parasite interface","volume":"15","author":"Reed SG","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.4049\/jimmunol.150.6.2322","article-title":"Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis","volume":"150","author":"Rachamim N","year":"1993","journal-title":"J Immunol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1645\/0022-3395(2000)086[0730:IOPPAL]2.0.CO;2","article-title":"Induction of partial protection against Leishmania donovani by promastigote antigens in negatively charged liposomes","volume":"86","author":"Afrin F","year":"2000","journal-title":"J Parasitol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2180-14-8","article-title":"IL-4 contributes to failure, and colludes with IL-10 to exacerbate Leishmania donovani infection following administration of a subcutaneous leishmanial antigen vaccine","volume":"14","author":"Bhowmick S","year":"2014","journal-title":"BMC Microbiol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.micinf.2008.06.002","article-title":"Vaccination with the Leishmania major ribosomal proteins plus CpG oligodeoxynucleotides induces protection against experimental cutaneous leishmaniasis in mice","volume":"10","author":"Iborra S","year":"2008","journal-title":"Microbes Infect"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"938","DOI":"10.2174\/138945008786786091","article-title":"Discovery of novel vaccine candidates and drug targets against visceral leishmaniasis using proteomics and transcriptomics","volume":"9","author":"Kumari S","year":"2008","journal-title":"Curr Drug Targets"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"7064","DOI":"10.4049\/jimmunol.165.12.7064","article-title":"Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis","volume":"165","author":"St\u00e4ger S","year":"2000","journal-title":"J Immunol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.1016\/j.vaccine.2012.05.075","article-title":"Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis","volume":"30","author":"Agallou M","year":"2012","journal-title":"Vaccine"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1586\/erv.12.50","article-title":"Vaccine prospects of killed but metabolically active Leishmania against visceral leishmaniasis","volume":"11","author":"Das A","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1172\/JCI117767","article-title":"Effect of granulocyte-macrophage colony-stimulating factor in experimental visceral leishmaniasis","volume":"95","author":"Murray HW","year":"1995","journal-title":"J Clin Invest"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1128\/IAI.71.11.6499-6509.2003","article-title":"Recombinant Leishmania major secreting biologically active granulocyte-macrophage colony-stimulating factor survives poorly in macrophages in vitro and delays disease development in mice","volume":"71","author":"Dumas C","year":"2003","journal-title":"Infect Immun"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/pim.12287","article-title":"Prophylactic properties of a Leishmania-specific hypothetical protein in a murine model of visceral leishmaniasis","volume":"37","author":"Lage DP","year":"2015","journal-title":"Parasite Immunol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.actatropica.2015.11.006","article-title":"A new Leishmania-specific hypothetical protein, LiHyT, used as a vaccine antigen against visceral leishmaniasis","volume":"154","author":"Martins VT","year":"2016","journal-title":"Acta Trop"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0165-2478(90)90083-3","article-title":"Cellular mechanisms of nonspecific immunity to intracellular infection: cytokine-induced synthesis of toxic nitrogen oxides from L-arginine by macrophages and hepatocytes","volume":"25","author":"Green SJ","year":"1990","journal-title":"Immunol Lett"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-3024.2009.01102.x","article-title":"Genetic susceptibility to leishmanial infections: studies in mice and man","volume":"31","author":"Blackwell JM","year":"2009","journal-title":"Parasite Immunol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0165-2478(98)00132-1","article-title":"T-cell response in human leishmaniasis","volume":"65","author":"Kharazmi A","year":"1999","journal-title":"Immunol Lett"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.micpath.2004.11.002","article-title":"Immunopathogenesis of infection with the visceralizing Leishmania species","volume":"38","author":"Wilson ME","year":"2005","journal-title":"Microb Pathog"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"4804","DOI":"10.1128\/IAI.71.8.4804-4807.2003","article-title":"Both interleukin-4 (IL-4) and IL-4 receptor alpha signaling contribute to the development of hepatic granulomas with optimal antileishmanial activity","volume":"71","author":"St\u00e4ger S","year":"2003","journal-title":"Infect Immun"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1128\/IAI.61.7.2952-2959.1993","article-title":"Immune responses associated with susceptibility of C57BL\/10 mice to Leishmania amazonensis","volume":"61","author":"Afonso LC","year":"1993","journal-title":"Infect Immun"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.parint.2014.04.002","article-title":"A comparative evaluation of efficacy of chemotherapy, immunotherapy and immunochemotherapy in visceral leishmaniasis-an experimental study","volume":"63","author":"Joshi J","year":"2014","journal-title":"Parasitol Int"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.1016\/j.vaccine.2008.05.095","article-title":"Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein","volume":"26","author":"Fernandes AP","year":"2008","journal-title":"Vaccine"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0264-410X(01)00322-X","article-title":"Immunization with A2 protein results in a mixed Th1\/Th2 and a humoral response which protects mice against Leishmania donovani infections","volume":"20","author":"Ghosh A","year":"2001","journal-title":"Vaccine"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1128\/IAI.71.7.3988-3994.2003","article-title":"Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection","volume":"71","author":"Coelho EAF","year":"2003","journal-title":"Infect Immun"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.micinf.2007.05.012","article-title":"Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections","volume":"9","author":"Zanin FHC","year":"2007","journal-title":"Microbes Infect"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1016\/j.vaccine.2008.05.091","article-title":"Epitope mapping and protective immunity elicited by adenovirus expressing the Leishmania amastigote specific A2 antigen: correlation with IFN-\u03b3 and cytolytic activity by CD8+ T cells","volume":"26","author":"Resende DM","year":"2008","journal-title":"Vaccine"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1099\/jmm.0.029959-0","article-title":"Generation and evaluation of A2-expressing Lactococcus lactis live vaccines against Leishmania donovani in BALB\/c mice","volume":"60","author":"Yam KK","year":"2011","journal-title":"J Med Microbiol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.vaccine.2009.09.114","article-title":"Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis","volume":"28","author":"Mizbani A","year":"2009","journal-title":"Vaccine"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0264-410X(02)00189-5","article-title":"Recombinant cysteine proteinases-based vacines against Leishmania major in BALB\/c mice: the partial protection relies on interferon-gamma producing CD8(+) T lymphocyte activation","volume":"20","author":"Rafati S","year":"2002","journal-title":"Vaccine"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.vaccine.2003.11.014","article-title":"Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis","volume":"22","author":"Zadeh-Vakili A","year":"2004","journal-title":"Vaccine"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0166-6851(95)02500-6","article-title":"The Leishmania promastigote surface antigen 2 complex is differentially expressed during the parasite life cycle","volume":"74","author":"Handman E","year":"1995","journal-title":"Mol Biochem Parasitol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0264-410X(98)00075-9","article-title":"Vaccination with recombinant parasite surface antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection","volume":"16","author":"Sj\u00f6lander A","year":"1998","journal-title":"Vaccine"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0165-2478(99)00146-7","article-title":"The humoral immune response to the kinetoplastid membrane protein-11 in patients with American leishmaniasis and Chagas disease: prevalence of IgG subclasses and mapping of epitopes","volume":"70","author":"Trujillo C","year":"1999","journal-title":"Immunol Lett"},{"key":"ref52","first-page":"423","article-title":"Leishmaniasis vaccine candidates for development: a global overview","volume":"123","author":"Kamesipour A","year":"2006","journal-title":"Ind J Med Res"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.vaccine.2008.01.023","article-title":"Vaccine s for leishmaniasis in the fore coming 25 years","volume":"26","author":"Palatnik-de-Sousa CB","year":"2008","journal-title":"Vaccine"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1128\/IAI.73.2.812-819.2005","article-title":"Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis","volume":"73","author":"Aguilar-Be I","year":"2005","journal-title":"Infect Immun"},{"key":"ref55","article-title":"Antigenicity, immunogenicity and protective efficacy of three proteins expressed in the promastigote and amastigote stages of Leishmania infantum against visceral leishmaniasis","volume":"10","author":"Martins VT","year":"2015","journal-title":"PLoS One"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.trsl.2013.03.006","article-title":"New vaccines for neglected parasitic diseases and dengue","volume":"162","author":"Beaumier CM","year":"2013","journal-title":"Transl Res"},{"key":"ref57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002174","article-title":"Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis","volume":"7","author":"Saljoughian N","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.4049\/jimmunol.150.6.2322","article-title":"Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis","volume":"150","author":"Rachamim N","year":"1993","journal-title":"J Immunol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1017\/S0031182013001959","article-title":"Studies on the protective efficacy of second-generation vaccine along with standard antileishmanial drug in Leishmania donovani infected BALB\/c mice","volume":"141","author":"Joshi J","year":"2014","journal-title":"Parasitology"},{"key":"ref60","article-title":"Recombinant NAD-dependent SIR-2 protein of Leishmania donovani: immunobiochemical characterization as a potential vaccine against visceral leishmaniasis","volume":"9","author":"Baharia RK","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1128\/CVI.05024-11","article-title":"KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis","volume":"18","author":"Goto Y","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/IAI.70.8.4215-4225.2002","article-title":"Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis","volume":"70","author":"Coler RN","year":"2002","journal-title":"Infect Immun"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fpubh.2014.00099","article-title":"Vector saliva in vaccines for visceral leishmaniasis: a brief encounter of high consequence?","volume":"2","author":"Kamhawi S","year":"2014","journal-title":"Front Public Health"},{"key":"ref64","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa3043","article-title":"A sand fly salivary protein vaccine shows efficacy against vector-transmitted cutaneous leishmaniasis in non-human primates","volume":"7","author":"Oliveira F","year":"2015","journal-title":"Sci Transl Med"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1161\/ATVBAHA.112.253906","article-title":"Lufaxin, a novel factor Xa inhibitor from the salivary gland of the sand fly Lutzomyia longipalpis blocks protease activated receptor 2 activation and inhibits inflammation and thrombosis in vivo","volume":"32","author":"Collin N","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"7845","DOI":"10.1073\/pnas.0712153105","article-title":"Immunity to a salivary protein of a sand fly vector protects against the fatal outcome of visceral leishmaniasis in a hamster model","volume":"105","author":"Gomes R","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref67","article-title":"Characterization of glycolytic enzymes--rAldolase and rEnolase of Leishmania donovani, identified as Th1 stimulatory proteins, for their immunogenicity and immunoprophylactic efficacies against experimental visceral leishmaniasis","volume":"9","author":"Gupta R","year":"2014","journal-title":"PLoS One"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1016\/j.vaccine.2005.12.039","article-title":"Vaccination with a preparation based on recombinant cysteine peptidases and canine IL-12 does not protect dogs from infection with Leishmania infantum","volume":"24","author":"Poot J","year":"2006","journal-title":"Vaccine"},{"key":"ref69","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2008.08.065","article-title":"Cysteine proteinase type III is protective against Leishmania infantum infection in BALB\/c mice and highly antigenic in visceral leishmaniasis individuals","volume":"26","author":"Khoshgoo N","year":"2008","journal-title":"Vaccine"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.vaccine.2014.01.024","article-title":"Immunization with the Leishmania infantum recombinant cyclophilin protein 1 confers partial protection to subsequent parasite infection and generates specific memory T cells","volume":"32","author":"Santos-Gomes GM","year":"2014","journal-title":"Vaccine"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"699","DOI":"10.4049\/jimmunol.144.2.699","article-title":"Characterization of two proteins from Leishmania donovani and their use for vaccination against visceral leishmaniasis","volume":"144","author":"Jaffe CL","year":"1990","journal-title":"J Immunol"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.4049\/jimmunol.1102081","article-title":"Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-\u03b3 and IL-12 response in cured Leishmania-infected patients\/hamsters and protects hamsters against Leishmania challenge","volume":"187","author":"Kushawaha PK","year":"2011","journal-title":"J Immunol"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1128\/IAI.63.5.2062-2069.1995","article-title":"A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice","volume":"63","author":"Wilson ME","year":"1995","journal-title":"Infect Immun"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1756-3305-7-3","article-title":"Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis","volume":"2","author":"Ramirez L","year":"2014","journal-title":"Parasit Vectors"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1016\/j.vaccine.2004.02.007","article-title":"Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen","volume":"22","author":"Tewary P","year":"2004","journal-title":"Vaccine"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"5245","DOI":"10.1016\/j.vaccine.2005.07.001","article-title":"Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals","volume":"23","author":"Gradoni L","year":"2005","journal-title":"Vaccine"},{"key":"ref77","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2015.6","article-title":"From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE","volume":"4","author":"Coler RN","year":"2015","journal-title":"Clin Transl Immunology"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-2427(02)00315-X","article-title":"A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum","volume":"92","author":"Molano I","year":"2003","journal-title":"Vet Immunol Immunopathol"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/j.vaccine.2016.04.067","article-title":"Strategic evaluation of vaccine candidate antigens for the prevention of visceral leishmaniasis","volume":"34","author":"Duthie MS","year":"2016","journal-title":"Vaccine"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1017\/S0031182005009546","article-title":"Approaches for the identification of potential excreted\/secreted proteins of Leishmania major parasites","volume":"132","author":"Chenik M","year":"2006","journal-title":"Parasitology"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.molbiopara.2009.10.009","article-title":"Gel free analysis of the proteome of intracellular Leishmania mexicana","volume":"169","author":"Paape D","year":"2010","journal-title":"Mol Biochem Parasitol"},{"key":"ref82","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001430","article-title":"Identification of proteins in promastigote and amastigote-like Leishmania using an immunoproteomic approach","volume":"6","author":"Coelho VT","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1021\/pr101286y","article-title":"Analysis of Leishmania chagasi by 2-D difference gel electrophoresis (2-D DIGE) and immunoproteomic: identification of novel candidate antigens for diagnostic tests and vaccine","volume":"10","author":"Costa MM","year":"2011","journal-title":"J Proteome Res"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/s13071-015-0964-5","article-title":"A Leishmania-specific hypothetical protein expressed in both promastigote and amastigote stages of Leishmania infantum employed for the serodiagnosis of, and as a vaccine candidate against, visceral leishmaniasis","volume":"8","author":"Martins VT","year":"2015","journal-title":"Parasit Vectors"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0264-410X(02)00444-9","article-title":"Saponins, IL-12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis","volume":"21","author":"Santos WR","year":"2002","journal-title":"Vaccine"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1586\/14760584.2.2.239","article-title":"Development of a leishmaniasis vaccine: the importance of MPL","volume":"2","author":"Reed SG","year":"2000","journal-title":"Expert Rev Vaccines"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"8427","DOI":"10.1073\/pnas.160197797","article-title":"The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory\/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge","volume":"97","author":"Stobie L","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/ni1112","article-title":"Toll-like receptor control of the adaptive immune responses","volume":"5","author":"Iwasaki A","year":"2004","journal-title":"Nat Immunol"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3201\/eid0605.000502","article-title":"Antigenic variation in vector-borne pathogens","volume":"6","author":"Barbour AG","year":"2000","journal-title":"Emerg Infect Dis"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.vaccine.2011.11.005","article-title":"The development and clinical evaluation of second-generation leishmaniasis vaccines","volume":"30","author":"Duthie MS","year":"2012","journal-title":"Vaccine"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.actatropica.2016.03.011","article-title":"Cross-protective efficacy of Leishmania infantum LiHyD protein against tegumentary leishmaniasis caused by Leishmania major and Leishmania braziliensis species","volume":"158","author":"Lage DP","year":"2016","journal-title":"Acta Trop"}],"container-title":["Revista da Sociedade Brasileira de Medicina Tropical"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/rsbmt\/v49n4\/1678-9849-rsbmt-49-04-00398.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T22:31:06Z","timestamp":1692484266000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0037-86822016000400398&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":91,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S0037-86822016000400398"],"URL":"https:\/\/doi.org\/10.1590\/0037-8682-0120-2016","relation":{},"ISSN":["0037-8682"],"issn-type":[{"value":"0037-8682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8]]}}}